{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-138452","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.417738+00:00","generated_at":"2026-05-19T15:07:49.205322+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation","bullets":["U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).","Ruling came in patent litigation against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.","Protects Acadia's intellectual property for NUPLAZID, used to treat Parkinson's disease psychosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-138452","json":"https://secwatch.observer/filing/0001193125-25-138452.json","markdown":"https://secwatch.observer/filing/0001193125-25-138452.md","text":"https://secwatch.observer/filing/0001193125-25-138452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312525138452/0001193125-25-138452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312525138452/d73868d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:07:49.205322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}